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A b s t r A c t
The Department of Immunology-Histocompatibility of “Evagelismos” Hospital since 
its beginning in 1978 showed an interest for the study of patients with primary im-
munodeficiencies. The cases referred and diagnosed in the Department were mainly 
adult patients with primary antibody deficiencies. As the number of these cases in-
creased, the development of a Referral Center was begun. In 1999 The Central Health 
Council of Greece approved the establishment of a “Specialized Center for adult cas-
es with primary immunodeficiencies” as part of the Department of Immunology-His-
tocompatibility. However, it was only in 2007 that the Center was officially recognized 
by the Ministry of Health. The services provided by the Center included among oth-
ers complete laboratory investigation for the diagnosis and classification of primary 
immunodeficiency, an outpatient clinic, collaboration with other departments of the 
hospital for the replacement therapy of patients with intravenous infusions of immu-
noglobulin and their hospitalization for various complications of their disease. Dur-
ing 42 years of follow up, 208 cases with primary antibody deficiency were diagnosed 
which included 92 cases with common variable immunodeficiency, 78 with selective 
IgA-deficiency, 24 with IgG subclass deficiency, and 14 with IgA and IgG subclass 
deficiency. The building of a Registry of these patients according to the procedures 
outlined by the European Society for Immunodeficiencies had been started but it has 
not yet been completed. For its optimal function, this Center should be supported 
by the State in order to have the necessary specialized staff for the management of 
patients and a better organization for their hospitalization according to their needs.
I N t r O D U c t I O N
The field of primary immunodeficiencies (PIDs) since its emergence in the 1950s has 
been expanding with the accumulation of new knowledge and the development of spe-
cialized care for the patients. In order to adequately manage immunodeficient patients 
and provide a long-term follow up in most countries, immune deficiency clinics and 
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referral centers have been organized, and moreover primary 
immunodeficiency networks are operating at a national level. 
In Europe, the European Society for Immunodeficiencies 
(ESID) in 1994 started to build a Registry for these patients 
which is useful for various epidemiologic, therapeutic and 
genetic studies and improves diagnosis and therapy.1,2
Among the primary antibody deficiencies (PAD), common 
variable immunodeficiency (CVID) is the most interesting for 
several reasons. Although its prevalence is 1:25000-1:50000, 
CVID has an important clinical significance as it is the most 
common immunodeficiency that requires immediate medi-
cal intervention with replacement immunoglobulin therapy 
which improves the quality of life and the overall survival of 
patients. The diagnosis is usually made between the ages of 
20 and 40 years and only 20% of the patients are less than 20 
years of age. This means that this form of PID concerns mainly 
adults. Although severe recurrent infections are the main 
symptom of the disease, a great percentage of the patients 
manifest noninfectious complications, such as autoimmune 
hematological diseases, chronic diarrhea with malabsorption 
syndrome, chronic lung diseases and development of cancer 
or lymphoma which occasionally may be presenting symptoms. 
This clinical heterogeneity, which according to Chappel et al3 
defines five clinical phenotypes, leads to a delay in diagnosis 
of 6 to 7 years which aggravates the morbidity and survival of 
the patients.4 According to other studies, the mean diagnostic 
delay is of the order of 4 years.2,5
In this paper we are going to present our experience with 
cases of primary antibody deficiencies in adults and describe 
the stepwise development of a referral center for these patients.
F I r s t  c A s e  O F  c O M M O N  V A r I A b l e 
I M M U N O D e F I c I e N c Y  I N  A N  A D U l t  
I N  G r e e c e
The first case of CVID in an adult was diagnosed by our 
team in the year 1972 at the Immunology Laboratory of the 
Second Department of Medicine of the University of Athens, 
Hippokration Hospital.6 A woman (T.V.) 53 years of age was 
referred to our department by the gastrointestinal service 
with a history of pulmonary infections since childhood and 
symptoms of chronic diarrhea with malabsorption. Her body 
weight was 39 kg and the serum immunoglobulins (Igs) were 
IgG of 49 mg/dl, with absent IgA and IgM. Following these 
findings, she was started on treatment with preparations of 
gamma globulin 16% for intramuscular use (12 vials every 20 
days). In 1976 she suffered a severe anaphylactic shock and 
in spite of a desensitization treatment, the following year she 
manifested a second anaphylactic shock and was forced to 
discontinue gamma globulin therapy.
In August 1978 the central laboratory of the blood trans-
fusion service of the Swiss Red Cross in Bern sent us for a 
clinical trial their product of gamma globulin for intravenous 
use which was prepared from large plasma pools. The patient 
received 12 g I.V. immunoglobulin (3 g daily for 4 days) de-
livered in cycles every 20 days, which was well tolerated and 
her condition showed remarkable improvement. This I.V. 
immunoglobulin (IVIG) was later commercially available as 
“Sandoglobulin” by Sandoz Pharma Ltd, Basel. The patient 
continued this treatment but 6 years later she developed an 
incurable gastric cancer and succumbed to the disease and 
generalized metastases. This patient was thus the first case with 
PAD in Greece who received IVIG as replacement therapy. 
Soon afterwards we diagnosed several other cases of CVID 
with malabsorption syndrome.
s t U D Y  O F  A D U l t  c A s e s  W I t H 
p r I M A r Y  A N t I b O D Y  D e F I c I e N c I e s 
A t  t H e  I M M U N O l O G Y -
H I s t O c O M p A t I b I l I t Y  D e p A r t M F N t 
O F  e V A G e l I s M O s  H O s p I t A l
As a result of our interest in cases of PID, the number 
of adult cases diagnosed with CVID and selective IgA defi-
ciency kept increasing in the new setting of the Department 
of Immunology-Histocompatibility of “Evagelismos” hospital. 
At the same time cases requiring treatment with IVIG were 
admitted to the hospital for their infusions, mainly in clinics 
that were willing to accept such patients. According to pub-
lished data by the year 1994, we had diagnosed and managed 
29 cases with CVID, 14 of which suffered from malabsorption 
syndrome7 and 49 cases with selective IgA deficiency, 13 of 
which presented with autoimmune disease.8
In 1996, in order to offer a better care to these patients and 
organize their follow up, we submitted to the Administration of 
the hospital our plan for the development of a Referral Center 
for adult patients with PID as was the practice in Europe and 
other countries. The Administration decided to support this 
program and since 1997 an outpatient clinic for patients with 
PID was added to the responsibilities of the Department. 
Subsequently the Central Health Council of Greece following 
a petition of the “Society for Primary Immune Deficiencies in 
Greece” with its official No 26 Decision of its 147th Meeting/ 
11-3-1999 approved the establishment of a “Specialized Cen-
ter for adult patients with PID” as part of the Department of 
Immunology-Histocompatibility at Evagelismos Hospital with 
the prevision that the Center should secure at least 2 beds for 
the medical care of these patients and the necessary equipment 
and specialized staff. The Council informed for further actions 
the “Direction for the Development of Medical Units” of the 
Ministry of Health and Social Services. However, although 
we submitted further details and plans for the organization 
of the Center, it was only 8 years later that the Center was 
officially recognized by the Ministry of Health (Decision 
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No ΔΥ2Β/Γ.Π./51150/23-05-2007). Two similar centers for 
children were then established, one assigned to the Depart-
ment of Immunology-Histocompatibility at the Children’s 
Hospital “Agia Sofia” in Athens and another assigned to the 
First Pediatric University Clinic at the Hippokration Hospital 
in Thessaloniki.
D I A G N O s I s  A N D  M A N A G e M e N t 
O F  A D U l t  c A s e s  W I t H  p r I M A r Y 
A N t I b O D Y  D e F I c I e N c I e s  A t  t H e 
D e p A r t M e N t  O F  I M M U N O l O G Y - 
H I s t O c O M p A t I b I l I t Y  O F 
e V A G e l I s M O s  H O s p I t A l
The Department of Immunology-Histocompatibility of 
Evagelismos Hospital all these years, irrespective of the official 
recognition of the Center, has tried to fulfill all the required 
responsibilities towards the patients in spite of the lack of per-
sonnel and adequate financial support. The following services 
were provided: 1) Complete laboratory investigation for the 
diagnosis and classification of PID. 2) Outpatient Clinic for the 
follow up of the patients and the training of those that require 
subcutaneous injection of immunoglobulin. 3) Skin tests and 
immunizations for the investigation of immunologic responses. 
4) Collaboration with the Medical Departments of the Hospital 
for the admittance of patients that required treatment with 
IVIG. Initially it was the First Department of Medicine that of-
fered two beds for this purpose and subsequently the Third and 
then the Fifth Department of Medicine followed. 5) Coordina-
tion of the treatment and follow up of cases attending other 
specialized Medical Units of the Hospital (e.g. Departments of 
Hematology, Gastroenterology, Rheumatology, etc.), as well 
as patients attending other Hospitals in Athens or other parts 
of Greece. 6) Applied research for the study of demographic, 
phenotypic and genetic parameters of the patients. Various 
immunological techniques, such as lymphocyte immunopheno-
typing, lymphocyte functional tests, human leucocyte antigen 
(HLA) associations, were applied together with the evaluation 
of clinical findings for the investigation of the immunological 
profile of the patients which improves the diagnosis and their 
management. Some of the results of these studies have been 
reported and published.9-14 7) The building of a Registry of the 
patients according to the procedures outlined by the European 
Society for Immunodeficiencies (ESID).
p A r t I c I p A t I O N  I N  t H e  N e t W O r K 
F O r M e D  b Y  e s I D  F O r  t H e 
D e V e l O p M e N t  O F  A  e U r O p e A N 
r e G I s t r Y  F O r  p A t I e N t s  W I t H  p I D
The initiative of ESID to create a Registry for patients with 
PID with the collaboration of Referral Centers in European 
countries was started in 1994 in Sweden. 2 We started to collect 
and send our data soon afterwards and we decided to combine 
our data with those of the two Pediatric Referral Centers from 
Athens and Thessaloniki. We reported a total of 268 cases of 
PID that entered this Registry that until the year 1998 had 
amassed data of 7616 patients from 25 European countries.15 
In parallel to the collaboration with the ESID Registry, the 
three Centers decided to build a National Registry for Greek 
patients with PID. The accumulated data on 313 patients (190 
children and 123 adults) have been previously reported.16 
However, this program still awaits to be completed.
Until 2000 (27 years of follow up) our cohort of patients 
with PAD comprised a total of 158 cases. Details on the 
characteristics of these patients are shown in Tables 1 and 2. 
The analysis of 26 patients with CVID showed that the delay 
in diagnosis from the onset of symptoms ranged from 1 to 50 
years with a median of 9 years. During the subsequent 15 years, 
27 additional cases of CVID were diagnosed together with 22 
cases of selective IgA deficiency and one case of combined 
IgA and IgG subclass deficiency. Of the total number of 92 
cases with CVID during the 42 years of follow up, 14 died, 
whereas 27 were lost to follow up. It is interesting that during 
the evolution of their disease, 6 patients developed gastric 
cancer and 4 manifested malignant lymphomas.
The ESID Registry accumulated data on 9707 cases with 
PID from 26 European countries but subsequently it was 
substituted by a new database system which allows the docu-
mentation of patients into an online system and provides data 
for 206 different PIDs and the possibility to accept clinical, 
laboratory and therapeutic parameters as well as follow up 
tAble 1. Distribution of 158 patients with primary an-
tibody deficiency followed up for 27 years according to 
diagnostic classification
classification No of cases 
Common variable immunodeficiency 65
Selective IgA deficiency 56
IgG subclass deficiency 24
IgA and IgG subclass deficiency 13
tAble 2. Age at diagnosis of 65 patients with common 
variable immunodeficiency
Age (Years) No of cases
<20   5
20-40 29
41-60 22
>60   7
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data of the patients.2 The two Pediatric Referral Centers have 
started reporting cases with PIDs online in the internet based 
Registry and some of these data have been published.17,18
c O N c l U s I O N  A N D  F U t U r e 
p e r s r e c t I V e s
For the optimal operation of a Referral Center for PIDs 
two prerequisites are required: a minimum of specialized staff 
that will cover the immediate needs of all patients and a hos-
pital organization that will provide all the necessary services 
for the diagnostic and clinical aspects of their management.
In our case, besides the laboratory technicians, there is only 
one medical doctor who is in charge of the Center. Moreo-
ver there is no provision for the time being for a Day Clinic 
which is needed for the I.V. immunoglobulin infusions for the 
patients and no separate room with at least 2 beds for those 
that require hospitalization. Another important problem is the 
fact that there is no provision for the referral to the Center of 
the children with PIDs that reach adulthood and as a conse-
quence they are scattered in various Hospitals and are lost to 
follow up. A personal communication with the two Pediatric 
Referral Centers in Athens and Thessaloniki revealed that at 
least 15 and 25 cases respectively of children with PAD have 
reached adulthood. The fact that our patients with CVID have 
an increased incidence of gastric cancer compared to series 
of other countries2,4 indicates that more should be done for 
its prevention and early diagnosis and management. Finally, 
the role of a dedicated secretary is of utmost importance who 
will keep contact with the patients so that they are not lost to 
follow up and ensure the correct reporting to the new online 
ESID Registry. The awareness of the medical community of 
this group of rare diseases should be also increased so that 
there is no delay in diagnosis for adult patients with PAD. 
Unfortunately it is not a rare event to find undiagnosed and 
neglected cases to be admitted to hospitals with severe compli-
cations of their disease which should and could be prevented. 
All these observations and remarks outline that in order that 
the work done until now is optimized, this Center for adult 
cases with primary immunodeficiencies should be supported 
by the State as it contributes significantly to the maintenance 
of Public Health.
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